Deputy Director, Chief Medical Oncology and Chief Scientific Officer
Manmeet Ahluwalia, M.D., FACP, M.B.A., is the chief of solid tumor medical oncology, deputy director and chief scientific officer at Miami Cancer Institute. As a neuro-oncologist, Dr. Ahluwalia’s primary areas of research and patient care are primary tumors and brain metastases. He joined Miami Cancer Institute from the Cleveland Clinic, where he was the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology and the Head of Operations in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC). He also served as a professor in the Department of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University.
Dr. Ahluwalia helped develop a world-class clinical trials program for brain tumors at the Cleveland Clinic. These trials involved immunotherapy and precision medicine-based approaches to target genetic alterations that drive disease. His research has been published in over 175 peer-reviewed publications, including the JAMA, JAMA Oncology, Neuro-Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Nature Reviews Neurology, Nature Reviews and Nature Reviews Clinical Oncology. In 2016, he was selected to participate in the American Society of Clinical Oncology’s Leadership Development Program. This prestigious year-long program allowed Dr. Ahluwalia to work with the top leaders in oncology from all over the world. He and his colleagues designed research for patients, caregivers and other oncologists to help them advance the field of oncology. As part of this program, he also met with members of Congress on Capitol Hill to promote funding for cancer research.
Dr. Ahluwalia is fluent in English, Hindi and Punjabi. In addition to his medical degree, Dr. Ahluwalia holds a Master of Business Administration from Case Western Reserve and the Cleveland Clinic.
×
About Manmeet Ahluwalia
Manmeet Ahluwalia, M.D., FACP, M.B.A., is the chief of solid tumor medical oncology, deputy director and chief scientific officer at Miami Cancer Institute. As a neuro-oncologist, Dr. Ahluwalia’s primary areas of research and patient care are primary tumors and brain metastases. He joined Miami Cancer Institute from the Cleveland Clinic, where he was the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology and the Head of Operations in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC). He also served as a professor in the Department of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University.
Dr. Ahluwalia helped develop a world-class clinical trials program for brain tumors at the Cleveland Clinic. These trials involved immunotherapy and precision medicine-based approaches to target genetic alterations that drive disease. His research has been published in over 175 peer-reviewed publications, including the JAMA, JAMA Oncology, Neuro-Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Nature Reviews Neurology, Nature Reviews and Nature Reviews Clinical Oncology. In 2016, he was selected to participate in the American Society of Clinical Oncology’s Leadership Development Program. This prestigious year-long program allowed Dr. Ahluwalia to work with the top leaders in oncology from all over the world. He and his colleagues designed research for patients, caregivers and other oncologists to help them advance the field of oncology. As part of this program, he also met with members of Congress on Capitol Hill to promote funding for cancer research.
Dr. Ahluwalia is fluent in English, Hindi and Punjabi. In addition to his medical degree, Dr. Ahluwalia holds a Master of Business Administration from Case Western Reserve and the Cleveland Clinic.
| 2021 - Present | Deputy Director, Chief Scientific Officer and Chief of Solid Tumor Medical Oncology, Baptist Health South Florida ‐ Miami Cancer Institute | |
|
|
||
| 2017 - 2020 | Program Director, Neuro-Oncology Fellowship, Cleveland Clinic , Cleveland, Ohio | |
|
|
||
| 2015 - 2020 | Head of Operations, Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic , Cleveland, Ohio | |
|
|
||
| 2014 - 2020 | Director, brain metastasis research program, brain tumor and neuro-oncology center, Cleveland Clinic, Cleveland, Ohio | |
|
|
||
| 2013 - 2020 | Associate Director Clinical Trials, Operations, brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio | |
|
|
||
| 2009 - 2020 | Section Head , Neuro-Oncology Outcomes, Brain Tumors and Neuro-Oncology Center, Cleveland Clinic , Cleveland, Ohio | |
|
|
||
Disciplines
Grants
| 2020 - Present | RadxTools for assessing tumor treatment response on imaging |
| National Institute of Health (NIH) - NIH ITCR U01 | |
| $1,381,000 | |
| 2019 - Present | Phase II study of Pembrolizumab Plus Survaxm for glioblastoma at first recurrence |
| Merck | |
| $853,000 | |
| 2019 - 2025 | CNS Working Group Chair |
| NCI - 1013080 | |
| $187,000 | |
| 2020 - 2023 | RadxTools |
| NCI ITCR program - 1U01CA248226-01 | |
| 2019 - 2022 | Brain tumor research and therapeutic development |
| Cleveland Clinic | |
| $900,000 | |
| 2019 - 2022 | Phase II study of Regorafenib for Bevacizumab refractory Glioblastoma |
| Bayer | |
| $358,000 | |
| 2017 - 2022 | Phase I study of Ibrutinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and Glioblastoma |
| Pharmacyclics | |
| $636,217 | |
| 2017 - 2022 | Phase I study of Ruxolitinib with radiation and Temozolomide in patiens with newly diagnosed grade III gliomas and glioblastomas |
| Incyte | |
| $775,881 | |
| 2020 - 2021 | Phase 2 Trial of BXQ 350 in Recurrent Glioblastoma |
| Bexion Pharmaceuticals | |
| $300,000 | |
| 2018 - 2021 | Systems Biology Approach to Predicting and Assessing Response to Chemo-Radiation for Brain Tumors |
| Army Medical Research and Material Command (AMRMC) - W81XWH1810404 | |
| $24,878 | |
| 2017 - 2021 | A randomized phased two open label study of Nivolumab plus standard dose Bevacizumab versus Nivolumab and low dose Bevacizumab in recurrent glioblastoma |
| Cleveland Clinic | |
| $2,206,822 | |
| 2016 - 2021 | Phase I/II study of Osimertinib and stereotactic radio surgery in EGFR positive non-small-cell lung cancer with brain metastasis |
| Astrazeneca | |
| $708,056 | |
| 2014 - 2021 | Phase II study of SurVaxM in patients with newly diagnosed glioblastoma |
| Roswell Park Cancer Institute Alliance Foundation | |
| $1,250,000 | |
| 2019 - 2020 | Single Cell Sequencing in a Randomized Phase 2 open label study of Nivolumav plus standard dose Bevacizumab versus Nivolumav and low dose Bevacizumab and recurrent glioblastoma |
| Musella Foundation | |
| $100,000 | |
| 2017 - 2020 | Changes in the EGFR amplification and EGFRvlll expression between paired primary and recurrent glioblastomas: correlation with survival based on EGFR status and genomic analysis |
| Abbvie | |
| $295,000 | |
| 2017 - 2020 | Velosano Impact Award |
| Cleveland Clinic | |
| $200,000 | |
| 2013 - 2020 | Phase II study of A Prospective Phase II Trial of NovoTTF-100A with Bevacizumab (Avastin) in Patients with Recurrent Glioblastoma The goal of this study is to determine |
| Novocure | |
| $611,140 | |
| 2018 - 2019 | Targeting Oncogenic Dopamine Receptor and Glioblastoma |
| National Cancer institute | |
| 2017 - 2018 | Cooperating pathways and glioblastoma stem cells |
| NIH - NINDS | |
| 2009 - 2013 | Therapeutic Studies of Primary CNS Malignancies - Adult Brain Tumor Consortium (ABTC) |
| Adult Brain Tumor Consortium (ABTC) |
Professional Service and Affiliations
| Member, American Association for Cancer Research | Member, American College of Physicians | Member, American Society of Clinical Oncology | Member, Society for Neuro-Oncology |
Honors and Awards
- Research Center of Excellence Co-Leader (Brain Tumor Research and Therapeutic Development Center, Cleveland Clinic, Ohio (2019-22)
- Velsano Impact Award, Brain Metastases Program (2017-18)
- Crains Forty Under 40, Northeast Ohio (2017)
- American Society of Clinical Oncology Leadership Development Program Award (2015-16)
- Indo-American Cancer Association Rising Star Award for Contribution to Oncology (2016)
- American Society of Clinical Oncology Taxonomy Task Force Member (2016)
- Leading in Healthcare, Cleveland Clinic (2015-16)
- Dean and Diane Miller Family Endowed Chair in Neuro-Oncology (2015-2019)
- Dean and Diane Miller Family Endowed Chair in Neuro-Oncology (2015-2019)
- US News and Castle Connolly's Top Doctor (2012-19)
- US News and Castle Connolly's Top Doctor (2012-19)
- *Refer to CV for additional Honors & Awards*
Courses
- Test
- 2009 - 2010 Clinical Instructor, Department of Medicine Cleveland Clinic Lerner College of Medicine Case Western Reserve University, Cleveland Clinic, Cleveland, OH
- 2010-2011 Visiting Assistant Professor, Department of Medicine Cleveland Clinic Lerner College of Medicine Case Western Reserve University, Cleveland Clinic, Cleveland, OH
- 2011-2014 Assistant Professor of Medicine Cleveland Clinic Lerner College of Medicine Case Western Reserve University, Cleveland Clinic, Cleveland, OH
- 2014-2017 Associate Professor of Medicine. Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland Clinic, Cleveland OH
- 2017-2020 Miller Family Endowed Chair in Neuro-Oncology Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland Clinic, Cleveland OH
- 2021-Present Translational Medicine. Herbert Wertheim College of Medicine, Florida International University, Miami, FL
| July 2018 - June 2020 | M.B.A., Business Administration (Healthcare track), Case Western Reserve University | |
|
|
||
| July 2006 - June 2009 | Fellowship Program - Hematology Oncology, Roswell Park Center Institute | |
|
|
||
| July 2003 - June 2006 | Residency Program - Internal Medicine, Fairview Hospital ‐ Cleveland Clinic Health System | |
|
|
||
| February 2002 - June 2003 | Research Fellowship, University of Toronto ‐ Department of Pathobiology & Laboratory Medicine | |
|
|
||
| July 1995 - December 2000 | Medicine & Surgery, M.B.B.S., University of Delhi ‐ Maulana Azad Medical College | |
|
|
||
| July 1993 - June 1995 | Senior, Secondary Examination, Delhi Public School | |
|
|
||
Contact Information
Miami Cancer Institute
8900 North Kendall Drive
Miami, FL 33176
(786) 596-2000
ManmeetA@baptisthealth.net